Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2be0b506fc902ca6c335841d7104b082 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6869 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
filingDate |
2019-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73bd6f97df01b326abc93933f1dd69f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6611a92657c92d5595b22cbfbbeaaa40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51989b2f7400f10f37e738e3120de61d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00744278820a0e43ee4b68c82519c9dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1faba8e0204f5f281b2f386b554e49a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20bb45f4839b3007a5c6ddaec8f36a9c |
publicationDate |
2022-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11278593-B2 |
titleOfInvention |
Composition and methods for the treatment of degenerative retinal conditions |
abstract |
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation. |
priorityDate |
2011-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |